Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a note from CEO and inventor Jim Joyce detailing CardioDialysis, a medical device designed to reduce major adverse cardiovascular events (MACE). Cardiovascular disease remains the leading cause of death worldwide, and current therapies like statins reduce MACE by only about 25%. In contrast, lipoprotein apheresis devices can reduce MACE by 75-95%, according to the American Heart Association. However, their adoption has been limited by complex, multi-component designs.
CardioDialysis aims to overcome these limitations by integrating plasma separation and therapeutic adsorption into a single device that can be deployed on existing dialysis machines. This eliminates the need for specialized apheresis centers and auxiliary components. For comparison, the Kaneka LIPOSORBER procedure requires a plasma separation column, two cartridges, custom tubing sets, a blood warmer, multiple bags of fluids, four waste bags, and several pumps. Access to this treatment is restricted to fewer than 60 specialized centers in the United States. In contrast, CardioDialysis can be used in over 5,000 hospitals and 7,500 dialysis clinics nationwide.
CardioDialysis continuously clears a broad spectrum of inflammatory and pathogenic molecules from the bloodstream. It targets not only LDL-C and Lipoprotein(a) but also inflammatory mediators that fuel cardiovascular disease progression. This broad-spectrum approach could address limitations of single-target drugs. Given that 15-20% of MACE result in death, successful clinical advancement of CardioDialysis could save thousands of lives annually.
Sigyn Therapeutics is also developing ImmunePrep to optimize immunotherapeutic antibody delivery, ChemoPrep to enhance chemotherapy targeting, and ChemoPure to reduce chemotherapy toxicity. The company cautions that forward-looking statements involve risks and uncertainties, including clinical advancement, manufacturing, and capital requirements. More information is available at www.SigynTherapeutics.com.
